Christine Mikail Cvijic Sells 4,061 Shares of Neurogene (NASDAQ:NGNE) Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,061 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $34.82, for a total transaction of $141,404.02. Following the transaction, the chief financial officer directly owned 88,840 shares in the company, valued at approximately $3,093,408.80. The trade was a 4.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The stock was sold at an average price of $34.06, for a total transaction of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Price Performance

NGNE opened at $35.34 on Friday. The company has a market cap of $558.37 million, a PE ratio of -7.77 and a beta of 1.68. Neurogene Inc. has a twelve month low of $15.93 and a twelve month high of $37.27. The company has a 50-day moving average price of $29.39 and a 200 day moving average price of $23.33.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.09). As a group, sell-side analysts expect that Neurogene Inc. will post -5.63 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on NGNE shares. Canaccord Genuity Group dropped their price target on Neurogene to $180.00 and set a “buy” rating for the company in a research report on Monday, April 6th. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a report on Tuesday, June 9th. UBS Group set a $70.00 target price on shares of Neurogene in a report on Wednesday, June 3rd. Rodman & Renshaw started coverage on shares of Neurogene in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $84.83.

Institutional Trading of Neurogene

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its holdings in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after acquiring an additional 978 shares during the period. PNC Financial Services Group Inc. increased its position in Neurogene by 24.7% during the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after purchasing an additional 1,000 shares during the last quarter. ADAR1 Capital Management LLC increased its position in Neurogene by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock worth $531,000 after purchasing an additional 1,008 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Neurogene by 12.8% during the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after purchasing an additional 2,950 shares during the period. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.